No profile data available.
Caribou Biosciences, Inc. (CRBU) is a healthcare company in the medication development research industry, based in Berkeley, United States, with about 97 full-time employees.
It reported revenue of $9.99 million for fiscal year 2024, down 71.0% from fiscal year 2023, and net income of -$149.11 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $2.20 million, up 8.6% from a year before. United States was its largest region in fiscal year 2025, with 85% of revenue. Its market capitalization was $49.34 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.
Caribou Biosciences reported $9.99 million in revenue for fiscal year 2024, down 71.0% from $34.48 million in fiscal year 2023. In Q3 2025 revenue was $2.20 million.
United States: 85% of revenue by region in fiscal year 2025, followed by Rest of World (15%).
$49.34 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include Molecular Partners AG (MOLN), Insight Molecular Diagnostics Inc. (IMDX), MindWalk Holdings Corp. (HYFT), iBio, Inc. (IBIO).